Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSC | P53634 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719074 | 0.85 | PTGS2 (0.37) | CTSKCTSCPTGS1SRD5A2GPR119 | |
| SCHEMBL718908 | 0.79 | PTGS2 (0.46) | PTGS1GPR119PTGS2KIF11 | |
| SCHEMBL720584 | 0.78 | PTGS1 (0.38) | CTSKCTSCPTGS1SRD5A2GPR119 | |
| SCHEMBL720234 | 0.76 | KIF11 (0.44) | PTGS1PTGS2KIF11 | |
| SCHEMBL720365 | 0.76 | KIF11 (0.44) | PTGS1PTGS2KIF11 | |
| SCHEMBL718622 | 0.76 | HRH3 (0.41) | CTSKCTSCKMT2ACNR1CNR2 | |
| SCHEMBL390791 | 0.74 | GPR119 (0.64) | GPR119 | |
| SCHEMBL719735 | 0.74 | NAAA (0.38) | PTGS1GPR119PTGS2KIF11 | |
| SCHEMBL720225 | 0.73 | GPR119 (0.44) | PTGS1GPR119PTGS2 | |
| SCHEMBL720579 | 0.72 | PTGS2 (0.41) | PTGS1PTGS2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | CTSK 1604/4885CTSC 58/4885PTGS1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.